This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that
Daklinza® (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor
(in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults. This is the first positive opinion given by the CHMP for an NS5A complex inhibitor and will now be reviewed by the European Commission, which has the authority to approve medicines for the European Union (EU).
“Through Bristol-Myers Squibb’s Early Access Programs in Europe more than 2,000 HCV patients with advanced liver disease have already been treated with
Daklinza, in combination with sofosbuvir,” said Elliott Levy, Head of Specialty Development, Bristol-Myers Squibb. “We anticipate that, if approved,
Daklinza-based regimens will play a significant role in treating HCV patients with high unmet medical needs across Europe.”
Recently included in the European Association for the Study of the Liver’s (EASL) clinical practice guidelines for the management of HCV infection across genotypes, the EU marketing authorization application for
Daklinza has gone
through an accelerated review process. The positive CHMP opinion was based on data from multiple studies of
Daklinza with other HCV agents, including sofosbuvir, for the treatment of chronic hepatitis C.
Daklinza-based regimens are also pending in Japan and the U.S. A decision from Japan’s Pharmaceutical and Medical Devices Agency is expected soon, and the U.S. Food and Drug Administration has granted priority review status and set a target review date under the Prescription Drug User Fee Act (PDUFA) of November 30, 2014.
Ongoing and completed
Daklinza studies have included more than 5,500 patients in a variety of all-oral regimens and with the current interferon-based standard of care. Across clinical studies,
Daklinza-based regimens have been generally well tolerated with low rates of discontinuations across a range of patients.
About Hepatitis C
Globally, there are 150 million people infected with HCV and of that, an estimated 9 million people are living with hepatitis C in the European Union (EU). Hepatitis C is a virus that infects the liver and is transmitted through direct contact with infected blood and blood products. Up to 90 percent of those infected with hepatitis C will not spontaneously clear the virus and will become chronically infected. According to the World Health Organization, 20 percent of people with chronic hepatitis C will develop cirrhosis and, of those, about 5 to 7 percent of patients may ultimately die of the consequences of infection.